{"gene":"BCAM","run_date":"2026-04-28T17:12:38","timeline":{"discoveries":[{"year":1994,"finding":"BCAM (B-CAM) was identified as a novel member of the immunoglobulin superfamily with a V-V-C2-C2-C2 domain structure, cloned by expression cloning, and mapped to chromosome 19q13.2-13.3; its homology to cell adhesion molecules suggested a role in cell-cell or cell-matrix adhesion.","method":"cDNA expression cloning, sequence analysis, fluorescence in situ hybridization","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1 — original molecular cloning with structural characterization and chromosomal mapping","pmids":["7954395"],"is_preprint":false},{"year":2002,"finding":"Epinephrine and cAMP-dependent PKA signaling activates BCAM/Lu-mediated adhesion of sickle red blood cells (SS RBCs) to laminin; epinephrine acts via the β2-adrenergic receptor to elevate cAMP in SS RBCs, and soluble BCAM/Lu blocks this adhesion, implicating BCAM/Lu as a direct target of PKA signaling.","method":"Cell adhesion assays with agonist stimulation (forskolin, epinephrine), PKA inhibition, blocking with recombinant soluble BCAM/Lu, β2-adrenergic receptor antagonism","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple pharmacological interventions with specific blocking reagents, replicated across patient samples","pmids":["12506027"],"is_preprint":false},{"year":2004,"finding":"Rap1 GTPase, activated by the cAMP-dependent exchange factor Epac, promotes BCAM/Lu-mediated adhesion of SS RBCs to laminin; Epac-specific cAMP analog (8CPT-2-Me) activates Rap1 and increases SS RBC adhesion to laminin in an integrin-independent but BCAM/Lu-dependent manner.","method":"GTP-Rap1 pulldown assay, Epac-specific cAMP analog stimulation, adhesion blockade with soluble BCAM/Lu and anti-BCAM/Lu antibody, RGD peptide and anti-α4β1 controls","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — pathway placement by epistasis using specific pharmacological tools and blocking antibodies with multiple orthogonal readouts","pmids":["15613546"],"is_preprint":false},{"year":2006,"finding":"Endothelial Lu/BCAM glycoproteins serve as ligands for red blood cell α4β1 integrin; epinephrine-stimulated sickle RBCs adhere to endothelial Lu/BCAM via α4β1 under flow conditions, and this adhesion is inhibited by soluble Lu-Fc protein.","method":"Cell adhesion assays under static and flow conditions using transfected cells expressing Lu-Fc chimeric protein, antibody-mediated integrin activation, blocking with soluble Lu-Fc and VCAM-1-Fc","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — reconstituted adhesion assay with chimeric protein, flow conditions, and multiple blocking controls; replicated across primary HUVECs","pmids":["17158232"],"is_preprint":false},{"year":2007,"finding":"JAK2 V617F mutation in polycythemia vera leads to increased expression and constitutive phosphorylation of Lu/BCAM on RBCs, enhancing adhesion to laminin α5 and endothelial cells; transfection of K562 cells with JAK2 V617F confirmed phosphorylation and increased expression of Lu/BCAM.","method":"Flow cytometry, radiometric adhesion assay, video microscopy under flow, K562 transfection with JAK2 V617F, inhibitory antibodies against Lu/BCAM and laminin α5","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — functional validation by transfection with gain-of-function JAK2 mutant, multiple readouts including phosphorylation and adhesion assays","pmids":["17412890"],"is_preprint":false},{"year":2008,"finding":"Lu/BCAM long isoform cytoplasmic tail is phosphorylated by CKII, GSK3β, and PKA; PKA pathway effectors stimulate phosphorylation of this isoform in transfected K562 cells and induce cell adhesion to laminin10/11.","method":"Phosphorylation state analysis of Lu/BCAM cytoplasmic tail in transfected K562 cells, kinase inhibition studies, cell adhesion to laminin10/11","journal":"Transfusion clinique et biologique","confidence":"Medium","confidence_rationale":"Tier 2 — direct biochemical demonstration in transfected cells, but single lab review article summarizing prior findings","pmids":["18514010"],"is_preprint":false},{"year":2010,"finding":"Lu/BCAM interacts with the spectrin-based membrane skeleton in erythrocytes; disruption of Lu/BCAM-spectrin interaction in hereditary spherocytosis (HS) RBCs or by mutation of the RK573-574 motif leads to increased Lu/BCAM detergent extractability and enhanced laminin adhesion, demonstrating that spectrin binding negatively regulates Lu/BCAM-mediated adhesion.","method":"Triton extraction of membrane skeleton-associated Lu/BCAM, flow-based adhesion assays with soluble Lu/BCAM blockade, site-directed mutagenesis (RK573-574AA) in transfected K562 cells","journal":"British journal of haematology","confidence":"High","confidence_rationale":"Tier 1–2 — site-directed mutagenesis combined with cell fractionation and functional adhesion assays","pmids":["20092464"],"is_preprint":false},{"year":2011,"finding":"Lu/BCAM binds to non-erythroid αII-spectrin via its RK573-574 motif; disruption of this interaction (RK573-574AA mutation) enhances Lu/BCAM surface half-life and cell adhesion/spreading on laminin 511/521, and mediates actin reorganization via RhoA activation and stress fiber formation.","method":"Co-immunoprecipitation, alanine substitution mutagenesis (RK573-574AA), live imaging of MDCK cells, RhoA activation assay, phalloidin staining for actin","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1–2 — mutagenesis combined with Co-IP, RhoA functional assay, and actin imaging with multiple readouts","pmids":["21434869"],"is_preprint":false},{"year":2013,"finding":"BCAM is a transcriptional target repressed by the 14-3-3β-FBI1/Akirin2 oncogenic complex; BCAM functions as a suppressive oncoprotein in hepatoma cells, as BCAM expression in K2 hepatoma cells abolished anchorage-independent growth, migration, invasion, and tumorigenicity.","method":"Microarray expression analysis, luciferase reporter assay, chromatin immunoprecipitation (ChIP), BCAM overexpression in K2 hepatoma cells with functional readouts (soft agar, migration, invasion, tumorigenicity in vivo)","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — ChIP confirms promoter binding, loss-of-function by overexpression with multiple cellular phenotypes","pmids":["24223164"],"is_preprint":false},{"year":2014,"finding":"Lu/BCAM is the cellular receptor for E. coli Cytotoxic Necrotizing Factor 1 (CNF1); CNF1 amino acids 720-1014 bind Lu/BCAM, and cells deficient in Lu/BCAM but expressing p37LRP cannot bind CNF1, establishing Lu/BCAM as essential for toxin binding to the cell surface.","method":"Co-precipitation of cell surface molecules with tagged toxin, direct protein-protein interaction analysis, competition studies, Lu/BCAM-deficient cell experiments","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 1–2 — direct binding assay, competition, and loss-of-function (Lu/BCAM-deficient cells) all converge on the same conclusion","pmids":["24453976"],"is_preprint":false},{"year":2014,"finding":"Hydroxycarbamide (HC) decreases sickle reticulocyte adhesion to endothelial cells by activating phosphodiesterase 4A (PDE4A), which reduces cAMP levels and thereby decreases phosphorylation of endothelial Lu/BCAM despite increased Lu/BCAM expression.","method":"Adhesion assays with sickle reticulocytes on HC-treated human bone marrow and pulmonary microvascular endothelial cells, PDE4A expression analysis, cAMP measurement, Lu/BCAM phosphorylation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — mechanistic dissection linking HC → PDE4A → cAMP → Lu/BCAM phosphorylation → adhesion, with multiple readouts in primary cells","pmids":["24616094"],"is_preprint":false},{"year":2015,"finding":"BCAM forms a recurrent in-frame gene fusion with AKT2 in high-grade serous ovarian carcinoma (7% of cases); the BCAM-AKT2 fusion protein is membrane-associated, constitutively phosphorylated and activated, escapes regulation by external stimuli, and is oncogenic (induces focus formation via CRISPR/Cas9-generated chromosomal translocation).","method":"RNA-seq fusion detection, RT-PCR confirmation of in-frame fusion mRNA, Western blot for fusion protein and phosphorylation, kinase activity assay, CRISPR/Cas9-mediated chromosomal translocation, focus formation assay in OVCAR8 and HEK-293T","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 — direct protein detection, kinase activity, CRISPR-generated model, and oncogenic transformation assay; multiple orthogonal methods in one study","pmids":["25733895"],"is_preprint":false},{"year":2016,"finding":"BCAM and LAMA5 (laminin α5) mediate adhesion of KRAS-mutant colorectal cancer cells specifically to endothelial cells; genetic suppression or biochemical inhibition of either BCAM or LAMA5 impairs this adhesion, and BCAM-mimic peptides inhibit KRAS-mutant hepatic metastasis in mouse models.","method":"Phage display screen, immunohistochemistry, adhesion assays, siRNA knockdown, peptide competition, in vivo mouse metastasis model","journal":"Clinical cancer research","confidence":"High","confidence_rationale":"Tier 2 — genetic suppression, biochemical inhibition, and in vivo efficacy all supporting BCAM/LAMA5 as functional mediators of metastatic adhesion","pmids":["27143691"],"is_preprint":false},{"year":2017,"finding":"The Ig-like domain 2 of Lu/BCAM is the main interaction site for CNF1 toxin; surface plasmon resonance revealed a high-affinity interaction (KD = 2.8 nM); small-angle X-ray scattering defined a 6:1 Lu/BCAM:CNF1 stoichiometry in the receptor-toxin complex.","method":"Direct protein-protein interaction analysis, competition studies, surface plasmon resonance (SPR), small-angle X-ray scattering (SAXS)","journal":"Toxins","confidence":"High","confidence_rationale":"Tier 1 — SPR provides quantitative affinity; SAXS provides structural stoichiometry; domain mapping by competition studies","pmids":["29267242"],"is_preprint":false},{"year":2018,"finding":"CD239/BCAM (Lutheran/BCAM) is highly expressed in a subset of breast cancer cells and is internalized into these cells; an anti-CD239 human scFv-Fc antibody conjugated to diphtheria toxin fragment (fDT) selectively kills CD239-high breast cancer cells, demonstrating BCAM-mediated endocytosis.","method":"Flow cytometry, immunofluorescence, antibody internalization assay, ADC cytotoxicity assay with fDT conjugate in CD239-positive and -negative cancer cell lines","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — internalization directly demonstrated; ADC killing shows functional consequence, but single lab study","pmids":["29700410"],"is_preprint":false},{"year":2018,"finding":"Lu/BCAM adhesive capacity is regulated during erythrocyte aging by glycophorin-C-derived sialic acid residues that restrain Lu/BCAM in cis; loss of sialic acid (via neuraminidase or the Gerbich phenotype lacking glycophorin-C exon 3) releases Lu/BCAM to interact with laminin-α5. The sialic acid-binding site was identified within the third Ig-like domain of Lu/BCAM.","method":"Neuraminidase treatment, Gerbich phenotype donor RBCs, laminin-α5 binding assays, co-immunoprecipitation of glycophorin-C and Lu/BCAM, domain mapping by mutagenesis/truncation","journal":"Blood advances","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches including natural genetic variant, enzymatic manipulation, Co-IP, and domain mapping","pmids":["29344581"],"is_preprint":false},{"year":2018,"finding":"Lutheran (Lu)/BCAM regulates biliary tissue remodeling (ductular reaction, DR) during liver regeneration; Lu+ and Lu- biliary cells show opposite phenotypes in motility and duct formation; overexpression of Lu in Lu- biliary cells confers Lu+ phenotype; Lu-deficient mice show severe defects in DR.","method":"Isolation of Lu+ and Lu- biliary cells, in vitro duct formation and motility assays, Lu overexpression in Lu- cells, Lu knockout mouse liver injury model","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 — gain-of-function, loss-of-function (KO mouse), and primary cell assays across multiple disease models","pmids":["30059007"],"is_preprint":false},{"year":2022,"finding":"BCAM defines a primitive cytotrophoblast progenitor state in early placental development; BCAM enrichment or gene silencing results in enhanced or diminished organoid growth, respectively, establishing BCAM as a functional regulator of trophoblast progenitor maintenance.","method":"Single-cell RNA sequencing, lineage trajectory analysis, human trophoblast stem cell organoids, BCAM gain-of-function (enrichment) and loss-of-function (siRNA silencing) with organoid growth readout","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 — scRNA-seq trajectory defines state, with functional validation by both gain- and loss-of-function in organoid system","pmids":["35020896"],"is_preprint":false},{"year":2022,"finding":"BCAM expression in limbal epithelial progenitor cells is required for cellular migration and differentiation of corneal epithelium; BCAM is functionally required (knockdown impairs migration and differentiation), and its expression is regulated by the transcription factor p63.","method":"FACS isolation of BCAM+ cells, holoclone formation assay, corneal epithelial sheet generation, BCAM knockdown loss-of-function for migration and differentiation, ChIP or reporter assays for p63 regulation","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — loss-of-function with defined phenotypic readouts, upstream regulator identified, functional in primary progenitor system","pmids":["35947947"],"is_preprint":false},{"year":2024,"finding":"Histone lysine lactylation (Kla) epigenetically induces BCAM expression in oral squamous cell carcinoma (OSCC), and BCAM promotes tumor invasion, angiogenesis, and cisplatin resistance.","method":"TCGA/GEO database analysis, Cox model construction, functional assays for invasion, angiogenesis, and drug resistance in BCAM-manipulated OSCC cells","journal":"Oral diseases","confidence":"Low","confidence_rationale":"Tier 3–4 — bioinformatics-driven with some functional follow-up but limited mechanistic detail in the abstract","pmids":["39503345"],"is_preprint":false}],"current_model":"BCAM (Lutheran/basal cell adhesion molecule) is an immunoglobulin superfamily transmembrane glycoprotein that functions as a high-affinity receptor for laminin α5 chain; its adhesive activity is regulated post-translationally by PKA-dependent phosphorylation of its cytoplasmic tail (activated via the β2-adrenergic receptor/cAMP/Epac/Rap1 signaling axis), negatively regulated by interaction of its RK573-574 motif with spectrin and by cis-inhibition from glycophorin-C sialic acids, and it engages in heterotypic interactions including binding to α4β1 integrin on reticulocytes (promoting sickle cell–endothelium adhesion), serving as the cell-surface receptor for E. coli CNF1 toxin (via Ig-like domain 2, KD ~2.8 nM), and forming an oncogenic constitutively active membrane-tethered kinase fusion (BCAM-AKT2) in high-grade serous ovarian carcinoma; it also regulates cytoskeletal remodeling through a laminin 511/521 → Lu/BCAM → αII-spectrin → RhoA → actin stress fiber pathway and plays functional roles in trophoblast progenitor maintenance and corneal epithelial differentiation."},"narrative":{"teleology":[{"year":1994,"claim":"Molecular cloning established BCAM as an immunoglobulin superfamily member with a V-V-C2-C2-C2 ectodomain architecture, predicting a role in cell adhesion that became the foundation for all subsequent functional studies.","evidence":"cDNA expression cloning, sequence analysis, and FISH mapping to 19q13.2–13.3","pmids":["7954395"],"confidence":"High","gaps":["No ligand or binding partner identified at this stage","No functional adhesion assay performed"]},{"year":2002,"claim":"Demonstration that epinephrine/cAMP/PKA signaling activates Lu/BCAM-mediated sickle RBC adhesion to laminin established the first signaling pathway controlling BCAM adhesive function and linked the molecule to sickle cell vaso-occlusion.","evidence":"Pharmacological stimulation (epinephrine, forskolin), PKA inhibition, and soluble BCAM/Lu blocking in sickle RBC adhesion assays","pmids":["12506027"],"confidence":"High","gaps":["Specific phosphorylation sites on BCAM cytoplasmic tail not mapped","Downstream signaling intermediates between PKA and BCAM activation unresolved"]},{"year":2004,"claim":"Identification of Epac/Rap1 as the cAMP-dependent intermediate upstream of BCAM activation resolved the signaling cascade as β2AR → cAMP → Epac → Rap1 → Lu/BCAM, distinct from integrin-dependent pathways.","evidence":"Epac-specific cAMP analog stimulation, GTP-Rap1 pulldown, adhesion blockade with soluble BCAM/Lu and anti-BCAM antibody in sickle RBCs","pmids":["15613546"],"confidence":"High","gaps":["Direct physical interaction between Rap1 effectors and BCAM not shown","Whether Rap1 acts on BCAM trafficking or conformation remains unresolved"]},{"year":2006,"claim":"Discovery that endothelial Lu/BCAM serves as a counter-receptor for α4β1 integrin on sickle RBCs under flow revealed a heterotypic adhesion axis contributing to vaso-occlusion beyond the laminin interaction.","evidence":"Flow-based adhesion assays with Lu-Fc chimeric protein, integrin activation, and soluble Lu-Fc blockade on primary HUVECs","pmids":["17158232"],"confidence":"High","gaps":["Binding site on Lu/BCAM for α4β1 not mapped","Relative contribution of Lu/BCAM–integrin vs. Lu/BCAM–laminin axes in vivo not quantified"]},{"year":2007,"claim":"JAK2 V617F in polycythemia vera was shown to constitutively phosphorylate and upregulate Lu/BCAM, establishing a disease mechanism for abnormal erythrocyte adhesion in myeloproliferative neoplasms.","evidence":"Flow cytometry, adhesion assays, and K562 cells transfected with JAK2 V617F, with anti-Lu/BCAM blocking","pmids":["17412890"],"confidence":"High","gaps":["Direct JAK2-BCAM substrate relationship not demonstrated with purified kinase","Whether JAK2 V617F acts on the same cytoplasmic tail sites as PKA is unclear"]},{"year":2010,"claim":"Identification of the spectrin-binding RK573-574 motif as a negative regulator of BCAM adhesion explained how cytoskeletal anchorage restrains BCAM activity and why hereditary spherocytosis RBCs show enhanced laminin binding.","evidence":"Triton extraction, site-directed mutagenesis (RK573-574AA) in K562 cells, and flow-based adhesion assays","pmids":["20092464"],"confidence":"High","gaps":["Structural basis of spectrin–BCAM interaction not resolved","Whether PKA phosphorylation and spectrin binding are coordinated or independent remains unclear"]},{"year":2011,"claim":"Extending the spectrin-BCAM axis to non-erythroid cells, disruption of the RK573-574 motif was shown to enhance BCAM surface half-life and trigger a laminin 511/521 → Lu/BCAM → αII-spectrin → RhoA → actin stress fiber pathway, linking BCAM to cytoskeletal remodeling.","evidence":"Co-IP of αII-spectrin with BCAM, RK573-574AA mutagenesis in MDCK cells, RhoA activation assay, phalloidin staining","pmids":["21434869"],"confidence":"High","gaps":["Intermediary GEF connecting BCAM/spectrin disruption to RhoA activation not identified","Relevance of this pathway in vivo not tested"]},{"year":2013,"claim":"BCAM was identified as a transcriptional target repressed by the 14-3-3β–FBI1/Akirin2 oncogenic complex, and BCAM overexpression abolished anchorage-independent growth and tumorigenicity in hepatoma cells, revealing a context-dependent tumor-suppressive role.","evidence":"Microarray, ChIP for promoter binding, BCAM overexpression in K2 hepatoma cells with soft agar, migration, invasion, and xenograft assays","pmids":["24223164"],"confidence":"High","gaps":["Mechanism by which BCAM suppresses anchorage-independent growth not defined","Whether BCAM tumor-suppressive function depends on laminin binding unknown"]},{"year":2014,"claim":"Identification of Lu/BCAM as the essential cell-surface receptor for E. coli CNF1 toxin opened an unexpected role in host–pathogen interaction, with subsequent biophysical mapping placing the binding site on Ig-like domain 2 at 2.8 nM affinity.","evidence":"Co-precipitation with tagged toxin, Lu/BCAM-deficient cell assays (2014); SPR and SAXS stoichiometry determination (2017)","pmids":["24453976","29267242"],"confidence":"High","gaps":["Structural model of the BCAM–CNF1 interface at atomic resolution not available","Whether BCAM mediates CNF1 internalization or only surface binding is not fully resolved"]},{"year":2014,"claim":"Hydroxycarbamide was shown to reduce sickle cell adhesion by activating PDE4A to lower cAMP and decrease endothelial Lu/BCAM phosphorylation, providing a pharmacological mechanism linking to the PKA/Epac signaling axis.","evidence":"Adhesion assays on HC-treated endothelial cells, PDE4A expression, cAMP measurement, Lu/BCAM phosphorylation analysis","pmids":["24616094"],"confidence":"High","gaps":["Specific phosphorylation site(s) reduced by HC not mapped","In vivo relevance of PDE4A-BCAM axis in treated sickle cell patients not confirmed"]},{"year":2015,"claim":"Discovery of the recurrent BCAM–AKT2 fusion in ~7% of high-grade serous ovarian carcinomas demonstrated that BCAM's transmembrane domain can tether AKT2 kinase to the membrane, generating a constitutively active oncogenic kinase.","evidence":"RNA-seq fusion detection, RT-PCR, Western blot, kinase activity assay, CRISPR/Cas9-generated translocation in OVCAR8/HEK-293T, focus formation assay","pmids":["25733895"],"confidence":"High","gaps":["Downstream AKT2 substrates specifically activated by the fusion not characterized","Whether wild-type BCAM contributes to ovarian cancer biology independent of the fusion unknown"]},{"year":2016,"claim":"BCAM–LAMA5 interaction was shown to mediate KRAS-mutant colorectal cancer cell adhesion to endothelium and hepatic metastasis, extending the BCAM–laminin α5 adhesion axis to metastatic colonization.","evidence":"Phage display, siRNA knockdown, peptide competition, and in vivo mouse metastasis model","pmids":["27143691"],"confidence":"High","gaps":["Whether BCAM on tumor cells or endothelium is the critical partner in metastasis not fully dissected","Selectivity of BCAM-mimic peptides for KRAS-mutant vs. KRAS-wild-type tumors not established"]},{"year":2018,"claim":"Glycophorin-C sialic acids were identified as cis-inhibitors of BCAM adhesion, with loss of sialylation (neuraminidase or Gerbich phenotype) releasing BCAM to engage laminin α5; the sialic acid-binding site was mapped to the third Ig-like domain.","evidence":"Neuraminidase treatment, Gerbich phenotype donor RBCs, Co-IP of glycophorin-C with Lu/BCAM, and domain mapping","pmids":["29344581"],"confidence":"High","gaps":["Atomic-level structure of the sialic acid–Ig3 interaction not solved","Whether glycophorin-C cis-inhibition operates in non-erythroid cells unknown"]},{"year":2018,"claim":"Lu/BCAM was shown to distinguish functional biliary cell subsets and to be required for ductular reaction during liver regeneration, extending BCAM biology to tissue repair.","evidence":"Isolation of Lu+ and Lu− biliary cells, in vitro duct formation, Lu overexpression rescue, and Lu-knockout mouse liver injury model","pmids":["30059007"],"confidence":"High","gaps":["Whether BCAM signals through laminin α5 or an alternative ligand in biliary regeneration not determined","Downstream transcriptional programs driven by BCAM in biliary cells not defined"]},{"year":2022,"claim":"BCAM was established as a functional marker of primitive cytotrophoblast progenitors and limbal epithelial stem cells, with loss-of-function impairing progenitor maintenance, migration, and differentiation in organoid and sheet culture systems.","evidence":"scRNA-seq lineage trajectories, gain- and loss-of-function in trophoblast organoids (2022a); FACS, BCAM knockdown, and p63 ChIP in limbal epithelial cells (2022b)","pmids":["35020896","35947947"],"confidence":"High","gaps":["Signaling downstream of BCAM in progenitor maintenance not characterized","Whether BCAM ligand engagement (laminin α5) is required for the progenitor phenotype not tested"]},{"year":null,"claim":"Key unresolved questions include the structural basis of BCAM–laminin α5 and BCAM–spectrin interactions at atomic resolution, the identity of the GEF linking BCAM/spectrin to RhoA, how PKA phosphorylation and spectrin release are coordinated, and whether BCAM's progenitor-maintenance role in trophoblast and limbal cells proceeds through the same downstream signaling as its erythrocyte adhesion function.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution co-crystal structure of BCAM with any partner","Downstream signaling in progenitor/stem cell contexts not defined","In vivo genetic models addressing BCAM in sickle cell vaso-occlusion lacking"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[0,1,3,6,7,12]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[9,13]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,1,3,6,11,14,15]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,2,5,10]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[3,6,7,12]},{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[1,6,7,12,15]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[4,11,19]}],"complexes":[],"partners":["LAMA5","SPTA1","GYPC","ITGA4","RAP1A","AKT2"],"other_free_text":[]},"mechanistic_narrative":"BCAM (Lutheran/basal cell adhesion molecule) is an immunoglobulin superfamily transmembrane glycoprotein that functions as a high-affinity laminin α5-chain receptor and mediates cell–matrix and cell–cell adhesion in erythrocytes, endothelium, epithelia, and trophoblast progenitor cells [PMID:7954395, PMID:12506027, PMID:35020896, PMID:35947947]. Its adhesive activity is positively regulated by β2-adrenergic receptor/cAMP/Epac/Rap1/PKA signaling, which phosphorylates the cytoplasmic tail, and negatively regulated by spectrin binding at the RK573-574 motif and by cis-inhibition from glycophorin-C sialic acids, with spectrin dissociation activating a RhoA–actin stress fiber remodeling pathway [PMID:12506027, PMID:15613546, PMID:20092464, PMID:21434869, PMID:29344581]. BCAM also serves as the high-affinity cell-surface receptor for E. coli CNF1 toxin via its second Ig-like domain (KD ~2.8 nM), engages α4β1 integrin on reticulocytes to promote sickle cell–endothelium adhesion, and forms an oncogenic BCAM–AKT2 fusion kinase in high-grade serous ovarian carcinoma [PMID:24453976, PMID:29267242, PMID:17158232, PMID:25733895]. In tissue homeostasis, BCAM marks and functionally maintains trophoblast and limbal epithelial progenitor populations and regulates biliary ductular reaction during liver regeneration [PMID:35020896, PMID:35947947, PMID:30059007]."},"prefetch_data":{"uniprot":{"accession":"P50895","full_name":"Basal cell adhesion molecule","aliases":["Auberger B antigen","B-CAM cell surface glycoprotein","F8/G253 antigen","Lutheran antigen","Lutheran blood group glycoprotein"],"length_aa":628,"mass_kda":67.4,"function":"Transmembrane glycoprotein that functions as both a receptor and an adhesion molecule playing a crucial role in cell adhesion, motility, migration and invasion (PubMed:9616226, PubMed:31413112). Extracellular domain enables binding to extracellular matrix proteins, such as laminin, integrin and other ligands while its intracellular domain interacts with cytoskeletal proteins like hemoglobin, facilitating cell signal transduction (PubMed:17158232). Serves as a receptor for laminin alpha-5/LAMA5 to promote cell adhesion (PubMed:15975931). Mechanistically, JAK2 induces BCAM phosphorylation and activates its adhesion to laminin by stimulating a Rap1/AKT signaling pathway in the absence of EPOR (PubMed:23160466)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P50895/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BCAM","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CANX","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/BCAM","total_profiled":1310},"omim":[{"mim_id":"612773","title":"BASAL CELL ADHESION MOLECULE; BCAM","url":"https://www.omim.org/entry/612773"},{"mim_id":"600599","title":"KLF TRANSCRIPTION FACTOR 1; KLF1","url":"https://www.omim.org/entry/600599"},{"mim_id":"247420","title":"LUTHERAN NULL","url":"https://www.omim.org/entry/247420"},{"mim_id":"111200","title":"BLOOD GROUP--LUTHERAN SYSTEM; LU","url":"https://www.omim.org/entry/111200"},{"mim_id":"111150","title":"BLOOD GROUP--LUTHERAN INHIBITOR; INLU","url":"https://www.omim.org/entry/111150"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoli fibrillar center","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"blood vessel","ntpm":346.2},{"tissue":"kidney","ntpm":339.1}],"url":"https://www.proteinatlas.org/search/BCAM"},"hgnc":{"alias_symbol":["CD239","B-CAM","F8/G253"],"prev_symbol":["LU"]},"alphafold":{"accession":"P50895","domains":[{"cath_id":"2.60.40.10","chopping":"35-145","consensus_level":"high","plddt":89.2584,"start":35,"end":145},{"cath_id":"2.60.40.10","chopping":"149-262","consensus_level":"high","plddt":95.8582,"start":149,"end":262},{"cath_id":"2.60.40.10","chopping":"268-357","consensus_level":"high","plddt":90.8896,"start":268,"end":357},{"cath_id":"2.60.40.10","chopping":"363-446","consensus_level":"high","plddt":93.2733,"start":363,"end":446},{"cath_id":"2.60.40.10","chopping":"455-542","consensus_level":"high","plddt":85.9025,"start":455,"end":542}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P50895","model_url":"https://alphafold.ebi.ac.uk/files/AF-P50895-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P50895-F1-predicted_aligned_error_v6.png","plddt_mean":83.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BCAM","jax_strain_url":"https://www.jax.org/strain/search?query=BCAM"},"sequence":{"accession":"P50895","fasta_url":"https://rest.uniprot.org/uniprotkb/P50895.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P50895/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P50895"}},"corpus_meta":[{"pmid":"28076709","id":"PMC_28076709","title":"Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.","date":"2017","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28076709","citation_count":2436,"is_preprint":false},{"pmid":"33581798","id":"PMC_33581798","title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.","date":"2021","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/33581798","citation_count":851,"is_preprint":false},{"pmid":"36297404","id":"PMC_36297404","title":"[177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer.","date":"2022","source":"Pharmaceuticals (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/36297404","citation_count":206,"is_preprint":false},{"pmid":"27160225","id":"PMC_27160225","title":"Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate.","date":"2016","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/27160225","citation_count":131,"is_preprint":false},{"pmid":"12506027","id":"PMC_12506027","title":"Novel epinephrine and cyclic AMP-mediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesion.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12506027","citation_count":130,"is_preprint":false},{"pmid":"16847654","id":"PMC_16847654","title":"Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?","date":"2006","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/16847654","citation_count":126,"is_preprint":false},{"pmid":"17412890","id":"PMC_17412890","title":"Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu/BCAM.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17412890","citation_count":104,"is_preprint":false},{"pmid":"31652074","id":"PMC_31652074","title":"177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors.","date":"2019","source":"Expert review of gastroenterology & hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/31652074","citation_count":101,"is_preprint":false},{"pmid":"23486963","id":"PMC_23486963","title":"Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial.","date":"2013","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23486963","citation_count":92,"is_preprint":false},{"pmid":"29949416","id":"PMC_29949416","title":"Neuroendocrine Tumor Therapy: 177Lu-DOTATATE.","date":"2018","source":"AJR. American journal of roentgenology","url":"https://pubmed.ncbi.nlm.nih.gov/29949416","citation_count":90,"is_preprint":false},{"pmid":"39293461","id":"PMC_39293461","title":"Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study.","date":"2024","source":"The Lancet. Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/39293461","citation_count":87,"is_preprint":false},{"pmid":"7954395","id":"PMC_7954395","title":"Molecular cloning of the B-CAM cell surface glycoprotein of epithelial cancers: a novel member of the immunoglobulin superfamily.","date":"1994","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/7954395","citation_count":78,"is_preprint":false},{"pmid":"32430671","id":"PMC_32430671","title":"Radiation doses from 161Tb and 177Lu in single tumour cells and micrometastases.","date":"2020","source":"EJNMMI physics","url":"https://pubmed.ncbi.nlm.nih.gov/32430671","citation_count":71,"is_preprint":false},{"pmid":"35020896","id":"PMC_35020896","title":"Cell trajectory modeling identifies a primitive trophoblast state defined by BCAM enrichment.","date":"2022","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/35020896","citation_count":58,"is_preprint":false},{"pmid":"27143691","id":"PMC_27143691","title":"BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer.","date":"2016","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/27143691","citation_count":58,"is_preprint":false},{"pmid":"15613546","id":"PMC_15613546","title":"Role of Rap1 in promoting sickle red blood cell adhesion to laminin via BCAM/LU.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15613546","citation_count":48,"is_preprint":false},{"pmid":"39060377","id":"PMC_39060377","title":"Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma.","date":"2024","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/39060377","citation_count":47,"is_preprint":false},{"pmid":"34242948","id":"PMC_34242948","title":"Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours.","date":"2021","source":"Nuclear medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/34242948","citation_count":46,"is_preprint":false},{"pmid":"17158232","id":"PMC_17158232","title":"Endothelial Lu/BCAM glycoproteins are novel ligands for red blood cell alpha4beta1 integrin: role in adhesion of sickle red blood cells to endothelial cells.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17158232","citation_count":45,"is_preprint":false},{"pmid":"25733895","id":"PMC_25733895","title":"Recurrent BCAM-AKT2 fusion gene leads to a constitutively activated AKT2 fusion kinase in high-grade serous ovarian carcinoma.","date":"2015","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25733895","citation_count":43,"is_preprint":false},{"pmid":"31757844","id":"PMC_31757844","title":"Imaging DNA Damage Repair In Vivo After 177Lu-DOTATATE Therapy.","date":"2019","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31757844","citation_count":43,"is_preprint":false},{"pmid":"36465905","id":"PMC_36465905","title":"AlphaBet: Combination of Radium-223 and [17 7Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol).","date":"2022","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36465905","citation_count":43,"is_preprint":false},{"pmid":"32062682","id":"PMC_32062682","title":"Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis.","date":"2020","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/32062682","citation_count":40,"is_preprint":false},{"pmid":"30725219","id":"PMC_30725219","title":"Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas.","date":"2019","source":"EJNMMI research","url":"https://pubmed.ncbi.nlm.nih.gov/30725219","citation_count":38,"is_preprint":false},{"pmid":"37111596","id":"PMC_37111596","title":"Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE.","date":"2023","source":"Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/37111596","citation_count":37,"is_preprint":false},{"pmid":"31195646","id":"PMC_31195646","title":"Evolution and Medical Significance of LU Domain-Containing Proteins.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31195646","citation_count":37,"is_preprint":false},{"pmid":"34026426","id":"PMC_34026426","title":"CD38-Targeted Theranostics of Lymphoma with 89Zr/177Lu-Labeled Daratumumab.","date":"2021","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/34026426","citation_count":37,"is_preprint":false},{"pmid":"29942399","id":"PMC_29942399","title":"Lu-177-Based Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors.","date":"2017","source":"Nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/29942399","citation_count":36,"is_preprint":false},{"pmid":"37097443","id":"PMC_37097443","title":"Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression.","date":"2023","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/37097443","citation_count":36,"is_preprint":false},{"pmid":"31039017","id":"PMC_31039017","title":"Therapy With 177Lu-DOTATATE: Clinical Implementation and Impact on Care of Patients With Neuroendocrine Tumors.","date":"2019","source":"AJR. American journal of roentgenology","url":"https://pubmed.ncbi.nlm.nih.gov/31039017","citation_count":36,"is_preprint":false},{"pmid":"24616094","id":"PMC_24616094","title":"Hydroxycarbamide decreases sickle reticulocyte adhesion to resting endothelium by inhibiting endothelial lutheran/basal cell adhesion molecule (Lu/BCAM) through phosphodiesterase 4A activation.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24616094","citation_count":35,"is_preprint":false},{"pmid":"34049983","id":"PMC_34049983","title":"Efficacy and Safety of 177Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study.","date":"2021","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34049983","citation_count":35,"is_preprint":false},{"pmid":"23271422","id":"PMC_23271422","title":"Nutritional and chemical composition and antiviral activity of cultivated seaweed Sargassum naozhouense Tseng et Lu.","date":"2012","source":"Marine drugs","url":"https://pubmed.ncbi.nlm.nih.gov/23271422","citation_count":33,"is_preprint":false},{"pmid":"24453976","id":"PMC_24453976","title":"Lu/BCAM adhesion glycoprotein is a receptor for Escherichia coli Cytotoxic Necrotizing Factor 1 (CNF1).","date":"2014","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/24453976","citation_count":33,"is_preprint":false},{"pmid":"30170196","id":"PMC_30170196","title":"Effects of adding an albumin binder chain on [177Lu]Lu-DOTATATE.","date":"2018","source":"Nuclear medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/30170196","citation_count":33,"is_preprint":false},{"pmid":"34575538","id":"PMC_34575538","title":"90Y/177Lu-DOTATOC: From Preclinical Studies to Application in Humans.","date":"2021","source":"Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/34575538","citation_count":31,"is_preprint":false},{"pmid":"34413147","id":"PMC_34413147","title":"Biokinetics and Dosimetry of 177Lu-Pentixather.","date":"2021","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34413147","citation_count":27,"is_preprint":false},{"pmid":"34301783","id":"PMC_34301783","title":"Intraarterial Administration Boosts 177Lu-HA-DOTATATE Accumulation in Salvage Meningioma Patients.","date":"2021","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34301783","citation_count":27,"is_preprint":false},{"pmid":"21154150","id":"PMC_21154150","title":"Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.","date":"2010","source":"IDrugs : the investigational drugs journal","url":"https://pubmed.ncbi.nlm.nih.gov/21154150","citation_count":27,"is_preprint":false},{"pmid":"32847972","id":"PMC_32847972","title":"Targeted Radionuclide Therapy in Patient-Derived Xenografts Using 177Lu-EB-RGD.","date":"2020","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/32847972","citation_count":27,"is_preprint":false},{"pmid":"38724277","id":"PMC_38724277","title":"Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE.","date":"2024","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38724277","citation_count":26,"is_preprint":false},{"pmid":"36297443","id":"PMC_36297443","title":"Glucose Metabolism Modification Induced by Radioligand Therapy with [177Lu]Lu/[90Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial.","date":"2022","source":"Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/36297443","citation_count":25,"is_preprint":false},{"pmid":"18514010","id":"PMC_18514010","title":"Role of Lu/BCAM in abnormal adhesion of sickle red blood cells to vascular endothelium.","date":"2008","source":"Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine","url":"https://pubmed.ncbi.nlm.nih.gov/18514010","citation_count":25,"is_preprint":false},{"pmid":"39266289","id":"PMC_39266289","title":"Preclinical Evaluation of 177Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors.","date":"2024","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39266289","citation_count":23,"is_preprint":false},{"pmid":"38062170","id":"PMC_38062170","title":"[177Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models.","date":"2023","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/38062170","citation_count":23,"is_preprint":false},{"pmid":"29344581","id":"PMC_29344581","title":"Glycophorin-C sialylation regulates Lu/BCAM adhesive capacity during erythrocyte aging.","date":"2018","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/29344581","citation_count":23,"is_preprint":false},{"pmid":"23168236","id":"PMC_23168236","title":"DARC (Duffy) and BCAM (Lutheran) reduced expression in thyroid cancer.","date":"2012","source":"Blood cells, molecules & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/23168236","citation_count":23,"is_preprint":false},{"pmid":"38587644","id":"PMC_38587644","title":"Targeting CXCR4/CXCL12 axis via [177Lu]Lu-DOTAGA.(SA.FAPi)2 with CXCR4 antagonist in triple-negative breast cancer.","date":"2024","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/38587644","citation_count":22,"is_preprint":false},{"pmid":"36534192","id":"PMC_36534192","title":"Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy.","date":"2022","source":"EJNMMI research","url":"https://pubmed.ncbi.nlm.nih.gov/36534192","citation_count":22,"is_preprint":false},{"pmid":"31545614","id":"PMC_31545614","title":"[68Ga]Ga/[177Lu]Lu-BL01, a Novel Theranostic Pair for Targeting C-X-C Chemokine Receptor 4.","date":"2019","source":"Molecular pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/31545614","citation_count":22,"is_preprint":false},{"pmid":"34046615","id":"PMC_34046615","title":"Formulation and clinical translation of [177Lu]Lu-trastuzumab for radioimmunotheranostics of metastatic breast cancer.","date":"2020","source":"RSC medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34046615","citation_count":22,"is_preprint":false},{"pmid":"37169534","id":"PMC_37169534","title":"[177Lu]Lu-PSMA-Radioligand Therapy Efficacy Outcomes in Taxane-Naïve Versus Taxane-Treated Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Metaanalysis.","date":"2023","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37169534","citation_count":22,"is_preprint":false},{"pmid":"37290797","id":"PMC_37290797","title":"Specific Uptake in the Bone Marrow Causes High Absorbed Red Marrow Doses During [177Lu]Lu-DOTATATE Treatment.","date":"2023","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37290797","citation_count":22,"is_preprint":false},{"pmid":"20092464","id":"PMC_20092464","title":"Role of the interaction between Lu/BCAM and the spectrin-based membrane skeleton in the increased adhesion of hereditary spherocytosis red cells to laminin.","date":"2010","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/20092464","citation_count":21,"is_preprint":false},{"pmid":"24223164","id":"PMC_24223164","title":"The FBI1/Akirin2 target gene, BCAM, acts as a suppressive oncogene.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24223164","citation_count":21,"is_preprint":false},{"pmid":"37171633","id":"PMC_37171633","title":"The predictive value of pretherapy [68Ga]Ga-DOTA-TATE PET and biomarkers in [177Lu]Lu-PRRT tumor dosimetry.","date":"2023","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/37171633","citation_count":21,"is_preprint":false},{"pmid":"32005767","id":"PMC_32005767","title":"In Vivo Instability of 177Lu-DOTATATE During Peptide Receptor Radionuclide Therapy.","date":"2020","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32005767","citation_count":21,"is_preprint":false},{"pmid":"39430616","id":"PMC_39430616","title":"Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial.","date":"2024","source":"EClinicalMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/39430616","citation_count":20,"is_preprint":false},{"pmid":"31149033","id":"PMC_31149033","title":"Preclinical efficacy of hK2 targeted [177Lu]hu11B6 for prostate cancer theranostics.","date":"2019","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/31149033","citation_count":20,"is_preprint":false},{"pmid":"21434869","id":"PMC_21434869","title":"Novel role for the Lu/BCAM-spectrin interaction in actin cytoskeleton reorganization.","date":"2011","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/21434869","citation_count":19,"is_preprint":false},{"pmid":"32859703","id":"PMC_32859703","title":"Multimodal Imaging of 2-Cycle PRRT with 177Lu-DOTA-JR11 and 177Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model.","date":"2020","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32859703","citation_count":19,"is_preprint":false},{"pmid":"34503959","id":"PMC_34503959","title":"Modeling Early Radiation DNA Damage Occurring During 177Lu-DOTATATE Radionuclide Therapy.","date":"2021","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34503959","citation_count":18,"is_preprint":false},{"pmid":"37500260","id":"PMC_37500260","title":"Single-Time-Point Imaging for Dosimetry After [177Lu]Lu-DOTATATE: Accuracy of Existing Methods and Novel Data-Driven Models for Reducing Sensitivity to Time-Point Selection.","date":"2023","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37500260","citation_count":18,"is_preprint":false},{"pmid":"33042258","id":"PMC_33042258","title":"Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [177Lu]Lu-PP-F11N.","date":"2020","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/33042258","citation_count":18,"is_preprint":false},{"pmid":"20655789","id":"PMC_20655789","title":"Role of Lu/BCAM glycoproteins in red cell diseases.","date":"2010","source":"Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine","url":"https://pubmed.ncbi.nlm.nih.gov/20655789","citation_count":17,"is_preprint":false},{"pmid":"38135849","id":"PMC_38135849","title":"Theranostic role of 89Zr- and 177Lu-labeled aflibercept in breast cancer.","date":"2023","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/38135849","citation_count":17,"is_preprint":false},{"pmid":"35947947","id":"PMC_35947947","title":"Limbal BCAM expression identifies a proliferative progenitor population capable of holoclone formation and corneal differentiation.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/35947947","citation_count":16,"is_preprint":false},{"pmid":"38646643","id":"PMC_38646643","title":"Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [177Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside.","date":"2024","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/38646643","citation_count":16,"is_preprint":false},{"pmid":"32577838","id":"PMC_32577838","title":"Extravasation of [177Lu]Lu-DOTATOC: case report and discussion.","date":"2020","source":"EJNMMI research","url":"https://pubmed.ncbi.nlm.nih.gov/32577838","citation_count":16,"is_preprint":false},{"pmid":"39947918","id":"PMC_39947918","title":"Dosimetry of [177Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial.","date":"2025","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39947918","citation_count":16,"is_preprint":false},{"pmid":"29414891","id":"PMC_29414891","title":"Norisoprenoids from the Brown Alga Sargassum naozhouense Tseng et Lu.","date":"2018","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/29414891","citation_count":16,"is_preprint":false},{"pmid":"37173878","id":"PMC_37173878","title":"Radionuclide Therapy of HER2-Expressing Xenografts Using [177Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/37173878","citation_count":16,"is_preprint":false},{"pmid":"33452632","id":"PMC_33452632","title":"Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC.","date":"2021","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/33452632","citation_count":15,"is_preprint":false},{"pmid":"36500804","id":"PMC_36500804","title":"Toxicity Assessment of [177Lu]Lu-iFAP/iPSMA Nanoparticles Prepared under GMP-Compliant Radiopharmaceutical Processes.","date":"2022","source":"Nanomaterials (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/36500804","citation_count":14,"is_preprint":false},{"pmid":"32661830","id":"PMC_32661830","title":"Evaluation of [131I]I- and [177Lu]Lu-DTPA-A11 Minibody for Radioimmunotherapy in a Preclinical Model of PSCA-Expressing Prostate Cancer.","date":"2020","source":"Molecular imaging and biology","url":"https://pubmed.ncbi.nlm.nih.gov/32661830","citation_count":14,"is_preprint":false},{"pmid":"37389800","id":"PMC_37389800","title":"First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs.","date":"2023","source":"EJNMMI radiopharmacy and chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37389800","citation_count":14,"is_preprint":false},{"pmid":"34200197","id":"PMC_34200197","title":"Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody® Molecules 177Lu-ABY-271 and 177Lu-ABY-027: Impact of DOTA Position on ABD Domain.","date":"2021","source":"Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/34200197","citation_count":13,"is_preprint":false},{"pmid":"29700410","id":"PMC_29700410","title":"Internalization of CD239 highly expressed in breast cancer cells: a potential antigen for antibody-drug conjugates.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29700410","citation_count":13,"is_preprint":false},{"pmid":"19005602","id":"PMC_19005602","title":"Targeting DNA with \"light-up\" pyrimidine triple-helical forming oligonucleotides conjugated to stabilizing fluorophores (LU-TFOs).","date":"2008","source":"Organic & biomolecular chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19005602","citation_count":13,"is_preprint":false},{"pmid":"29267242","id":"PMC_29267242","title":"High Affinity Binding of Escherichia coli Cytotoxic Necrotizing Factor 1 (CNF1) to Lu/BCAM Adhesion Glycoprotein.","date":"2017","source":"Toxins","url":"https://pubmed.ncbi.nlm.nih.gov/29267242","citation_count":12,"is_preprint":false},{"pmid":"35347483","id":"PMC_35347483","title":"Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [177Lu]Lu-DOTATATE.","date":"2022","source":"EJNMMI physics","url":"https://pubmed.ncbi.nlm.nih.gov/35347483","citation_count":12,"is_preprint":false},{"pmid":"33552155","id":"PMC_33552155","title":"The Safety and Efficacy of the Repeated PRRT with [90Y]Y/[177Lu]Lu-DOTATATE in Patients with NET.","date":"2021","source":"International journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33552155","citation_count":12,"is_preprint":false},{"pmid":"28194794","id":"PMC_28194794","title":"Mutations of the KLF1 gene detected in Japanese with the In(Lu) phenotype.","date":"2017","source":"Transfusion","url":"https://pubmed.ncbi.nlm.nih.gov/28194794","citation_count":12,"is_preprint":false},{"pmid":"36831477","id":"PMC_36831477","title":"Correlations between [68Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [177Lu]Lu-DOTA-TATE.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36831477","citation_count":11,"is_preprint":false},{"pmid":"37242475","id":"PMC_37242475","title":"Characterization of Non-Specific Uptake and Retention Mechanisms of [177Lu]Lu-PSMA-617 in the Salivary Glands.","date":"2023","source":"Pharmaceuticals (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/37242475","citation_count":11,"is_preprint":false},{"pmid":"39023784","id":"PMC_39023784","title":"Combining [177Lu]Lu-DOTA-TOC PRRT with PARP inhibitors to enhance treatment efficacy in small cell lung cancer.","date":"2024","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/39023784","citation_count":10,"is_preprint":false},{"pmid":"30059007","id":"PMC_30059007","title":"Differential expression of Lutheran/BCAM regulates biliary tissue remodeling in ductular reaction during liver regeneration.","date":"2018","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/30059007","citation_count":10,"is_preprint":false},{"pmid":"38528164","id":"PMC_38528164","title":"Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours.","date":"2024","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/38528164","citation_count":10,"is_preprint":false},{"pmid":"34827693","id":"PMC_34827693","title":"p53-Mediated Radiosensitization of 177Lu-DOTATATE in Neuroblastoma Tumor Spheroids.","date":"2021","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/34827693","citation_count":10,"is_preprint":false},{"pmid":"37067162","id":"PMC_37067162","title":"Inhibition of Poly(ADP-ribose) Polymerase Sensitizes [177Lu]Lu-DOTAGA.(SA.FAPi)2-Mediated Radiotherapy in Triple-Negative Breast Cancer.","date":"2023","source":"Molecular pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/37067162","citation_count":10,"is_preprint":false},{"pmid":"39503345","id":"PMC_39503345","title":"Histone Lysine Lactylation (Kla)-induced BCAM Promotes OSCC Progression and Cis-Platinum Resistance.","date":"2024","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/39503345","citation_count":9,"is_preprint":false},{"pmid":"39978813","id":"PMC_39978813","title":"Therapy-Related Myeloid Neoplasms After [177Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series.","date":"2025","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39978813","citation_count":9,"is_preprint":false},{"pmid":"38069337","id":"PMC_38069337","title":"Radiobiological Assessment of Targeted Radionuclide Therapy with [177Lu]Lu-PSMA-I&T in 2D vs. 3D Cell Culture Models.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38069337","citation_count":9,"is_preprint":false},{"pmid":"16734819","id":"PMC_16734819","title":"Phage-derived monoclonal anti-Lu.","date":"2006","source":"Transfusion","url":"https://pubmed.ncbi.nlm.nih.gov/16734819","citation_count":9,"is_preprint":false},{"pmid":"38904444","id":"PMC_38904444","title":"Imaging and Downstaging Bladder Cancer with the 177Lu-Labeled Bioorthogonal Nanoprobe.","date":"2024","source":"ACS nano","url":"https://pubmed.ncbi.nlm.nih.gov/38904444","citation_count":9,"is_preprint":false},{"pmid":"38367588","id":"PMC_38367588","title":"A PBPK model for PRRT with [177Lu]Lu-DOTA-TATE: Comparison of model implementations in SAAM II and MATLAB/SimBiology.","date":"2024","source":"Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)","url":"https://pubmed.ncbi.nlm.nih.gov/38367588","citation_count":9,"is_preprint":false},{"pmid":"39778968","id":"PMC_39778968","title":"177Lu-DOTATATE Plus Capecitabine Versus 177Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial.","date":"2025","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39778968","citation_count":9,"is_preprint":false},{"pmid":"39978808","id":"PMC_39978808","title":"Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in Combination with [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer.","date":"2025","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39978808","citation_count":9,"is_preprint":false},{"pmid":"36342790","id":"PMC_36342790","title":"Efficacy of Everolimus Combined with 177Lu-Dotatate in the Treatment of Neuroendocrine Tumors.","date":"2022","source":"Cancer biotherapy & radiopharmaceuticals","url":"https://pubmed.ncbi.nlm.nih.gov/36342790","citation_count":9,"is_preprint":false},{"pmid":"39477495","id":"PMC_39477495","title":"Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [177Lu]Lu-PSMA-617.","date":"2024","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39477495","citation_count":8,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":65164,"output_tokens":5115,"usd":0.136108},"stage2":{"model":"claude-opus-4-6","input_tokens":8713,"output_tokens":4001,"usd":0.215385},"total_usd":0.351493,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"BCAM (B-CAM) was identified as a novel member of the immunoglobulin superfamily with a V-V-C2-C2-C2 domain structure, cloned by expression cloning, and mapped to chromosome 19q13.2-13.3; its homology to cell adhesion molecules suggested a role in cell-cell or cell-matrix adhesion.\",\n      \"method\": \"cDNA expression cloning, sequence analysis, fluorescence in situ hybridization\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original molecular cloning with structural characterization and chromosomal mapping\",\n      \"pmids\": [\"7954395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Epinephrine and cAMP-dependent PKA signaling activates BCAM/Lu-mediated adhesion of sickle red blood cells (SS RBCs) to laminin; epinephrine acts via the β2-adrenergic receptor to elevate cAMP in SS RBCs, and soluble BCAM/Lu blocks this adhesion, implicating BCAM/Lu as a direct target of PKA signaling.\",\n      \"method\": \"Cell adhesion assays with agonist stimulation (forskolin, epinephrine), PKA inhibition, blocking with recombinant soluble BCAM/Lu, β2-adrenergic receptor antagonism\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple pharmacological interventions with specific blocking reagents, replicated across patient samples\",\n      \"pmids\": [\"12506027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Rap1 GTPase, activated by the cAMP-dependent exchange factor Epac, promotes BCAM/Lu-mediated adhesion of SS RBCs to laminin; Epac-specific cAMP analog (8CPT-2-Me) activates Rap1 and increases SS RBC adhesion to laminin in an integrin-independent but BCAM/Lu-dependent manner.\",\n      \"method\": \"GTP-Rap1 pulldown assay, Epac-specific cAMP analog stimulation, adhesion blockade with soluble BCAM/Lu and anti-BCAM/Lu antibody, RGD peptide and anti-α4β1 controls\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pathway placement by epistasis using specific pharmacological tools and blocking antibodies with multiple orthogonal readouts\",\n      \"pmids\": [\"15613546\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Endothelial Lu/BCAM glycoproteins serve as ligands for red blood cell α4β1 integrin; epinephrine-stimulated sickle RBCs adhere to endothelial Lu/BCAM via α4β1 under flow conditions, and this adhesion is inhibited by soluble Lu-Fc protein.\",\n      \"method\": \"Cell adhesion assays under static and flow conditions using transfected cells expressing Lu-Fc chimeric protein, antibody-mediated integrin activation, blocking with soluble Lu-Fc and VCAM-1-Fc\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reconstituted adhesion assay with chimeric protein, flow conditions, and multiple blocking controls; replicated across primary HUVECs\",\n      \"pmids\": [\"17158232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"JAK2 V617F mutation in polycythemia vera leads to increased expression and constitutive phosphorylation of Lu/BCAM on RBCs, enhancing adhesion to laminin α5 and endothelial cells; transfection of K562 cells with JAK2 V617F confirmed phosphorylation and increased expression of Lu/BCAM.\",\n      \"method\": \"Flow cytometry, radiometric adhesion assay, video microscopy under flow, K562 transfection with JAK2 V617F, inhibitory antibodies against Lu/BCAM and laminin α5\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional validation by transfection with gain-of-function JAK2 mutant, multiple readouts including phosphorylation and adhesion assays\",\n      \"pmids\": [\"17412890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Lu/BCAM long isoform cytoplasmic tail is phosphorylated by CKII, GSK3β, and PKA; PKA pathway effectors stimulate phosphorylation of this isoform in transfected K562 cells and induce cell adhesion to laminin10/11.\",\n      \"method\": \"Phosphorylation state analysis of Lu/BCAM cytoplasmic tail in transfected K562 cells, kinase inhibition studies, cell adhesion to laminin10/11\",\n      \"journal\": \"Transfusion clinique et biologique\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct biochemical demonstration in transfected cells, but single lab review article summarizing prior findings\",\n      \"pmids\": [\"18514010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Lu/BCAM interacts with the spectrin-based membrane skeleton in erythrocytes; disruption of Lu/BCAM-spectrin interaction in hereditary spherocytosis (HS) RBCs or by mutation of the RK573-574 motif leads to increased Lu/BCAM detergent extractability and enhanced laminin adhesion, demonstrating that spectrin binding negatively regulates Lu/BCAM-mediated adhesion.\",\n      \"method\": \"Triton extraction of membrane skeleton-associated Lu/BCAM, flow-based adhesion assays with soluble Lu/BCAM blockade, site-directed mutagenesis (RK573-574AA) in transfected K562 cells\",\n      \"journal\": \"British journal of haematology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — site-directed mutagenesis combined with cell fractionation and functional adhesion assays\",\n      \"pmids\": [\"20092464\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Lu/BCAM binds to non-erythroid αII-spectrin via its RK573-574 motif; disruption of this interaction (RK573-574AA mutation) enhances Lu/BCAM surface half-life and cell adhesion/spreading on laminin 511/521, and mediates actin reorganization via RhoA activation and stress fiber formation.\",\n      \"method\": \"Co-immunoprecipitation, alanine substitution mutagenesis (RK573-574AA), live imaging of MDCK cells, RhoA activation assay, phalloidin staining for actin\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mutagenesis combined with Co-IP, RhoA functional assay, and actin imaging with multiple readouts\",\n      \"pmids\": [\"21434869\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BCAM is a transcriptional target repressed by the 14-3-3β-FBI1/Akirin2 oncogenic complex; BCAM functions as a suppressive oncoprotein in hepatoma cells, as BCAM expression in K2 hepatoma cells abolished anchorage-independent growth, migration, invasion, and tumorigenicity.\",\n      \"method\": \"Microarray expression analysis, luciferase reporter assay, chromatin immunoprecipitation (ChIP), BCAM overexpression in K2 hepatoma cells with functional readouts (soft agar, migration, invasion, tumorigenicity in vivo)\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP confirms promoter binding, loss-of-function by overexpression with multiple cellular phenotypes\",\n      \"pmids\": [\"24223164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Lu/BCAM is the cellular receptor for E. coli Cytotoxic Necrotizing Factor 1 (CNF1); CNF1 amino acids 720-1014 bind Lu/BCAM, and cells deficient in Lu/BCAM but expressing p37LRP cannot bind CNF1, establishing Lu/BCAM as essential for toxin binding to the cell surface.\",\n      \"method\": \"Co-precipitation of cell surface molecules with tagged toxin, direct protein-protein interaction analysis, competition studies, Lu/BCAM-deficient cell experiments\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct binding assay, competition, and loss-of-function (Lu/BCAM-deficient cells) all converge on the same conclusion\",\n      \"pmids\": [\"24453976\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Hydroxycarbamide (HC) decreases sickle reticulocyte adhesion to endothelial cells by activating phosphodiesterase 4A (PDE4A), which reduces cAMP levels and thereby decreases phosphorylation of endothelial Lu/BCAM despite increased Lu/BCAM expression.\",\n      \"method\": \"Adhesion assays with sickle reticulocytes on HC-treated human bone marrow and pulmonary microvascular endothelial cells, PDE4A expression analysis, cAMP measurement, Lu/BCAM phosphorylation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection linking HC → PDE4A → cAMP → Lu/BCAM phosphorylation → adhesion, with multiple readouts in primary cells\",\n      \"pmids\": [\"24616094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BCAM forms a recurrent in-frame gene fusion with AKT2 in high-grade serous ovarian carcinoma (7% of cases); the BCAM-AKT2 fusion protein is membrane-associated, constitutively phosphorylated and activated, escapes regulation by external stimuli, and is oncogenic (induces focus formation via CRISPR/Cas9-generated chromosomal translocation).\",\n      \"method\": \"RNA-seq fusion detection, RT-PCR confirmation of in-frame fusion mRNA, Western blot for fusion protein and phosphorylation, kinase activity assay, CRISPR/Cas9-mediated chromosomal translocation, focus formation assay in OVCAR8 and HEK-293T\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct protein detection, kinase activity, CRISPR-generated model, and oncogenic transformation assay; multiple orthogonal methods in one study\",\n      \"pmids\": [\"25733895\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BCAM and LAMA5 (laminin α5) mediate adhesion of KRAS-mutant colorectal cancer cells specifically to endothelial cells; genetic suppression or biochemical inhibition of either BCAM or LAMA5 impairs this adhesion, and BCAM-mimic peptides inhibit KRAS-mutant hepatic metastasis in mouse models.\",\n      \"method\": \"Phage display screen, immunohistochemistry, adhesion assays, siRNA knockdown, peptide competition, in vivo mouse metastasis model\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic suppression, biochemical inhibition, and in vivo efficacy all supporting BCAM/LAMA5 as functional mediators of metastatic adhesion\",\n      \"pmids\": [\"27143691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The Ig-like domain 2 of Lu/BCAM is the main interaction site for CNF1 toxin; surface plasmon resonance revealed a high-affinity interaction (KD = 2.8 nM); small-angle X-ray scattering defined a 6:1 Lu/BCAM:CNF1 stoichiometry in the receptor-toxin complex.\",\n      \"method\": \"Direct protein-protein interaction analysis, competition studies, surface plasmon resonance (SPR), small-angle X-ray scattering (SAXS)\",\n      \"journal\": \"Toxins\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — SPR provides quantitative affinity; SAXS provides structural stoichiometry; domain mapping by competition studies\",\n      \"pmids\": [\"29267242\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CD239/BCAM (Lutheran/BCAM) is highly expressed in a subset of breast cancer cells and is internalized into these cells; an anti-CD239 human scFv-Fc antibody conjugated to diphtheria toxin fragment (fDT) selectively kills CD239-high breast cancer cells, demonstrating BCAM-mediated endocytosis.\",\n      \"method\": \"Flow cytometry, immunofluorescence, antibody internalization assay, ADC cytotoxicity assay with fDT conjugate in CD239-positive and -negative cancer cell lines\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — internalization directly demonstrated; ADC killing shows functional consequence, but single lab study\",\n      \"pmids\": [\"29700410\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Lu/BCAM adhesive capacity is regulated during erythrocyte aging by glycophorin-C-derived sialic acid residues that restrain Lu/BCAM in cis; loss of sialic acid (via neuraminidase or the Gerbich phenotype lacking glycophorin-C exon 3) releases Lu/BCAM to interact with laminin-α5. The sialic acid-binding site was identified within the third Ig-like domain of Lu/BCAM.\",\n      \"method\": \"Neuraminidase treatment, Gerbich phenotype donor RBCs, laminin-α5 binding assays, co-immunoprecipitation of glycophorin-C and Lu/BCAM, domain mapping by mutagenesis/truncation\",\n      \"journal\": \"Blood advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches including natural genetic variant, enzymatic manipulation, Co-IP, and domain mapping\",\n      \"pmids\": [\"29344581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Lutheran (Lu)/BCAM regulates biliary tissue remodeling (ductular reaction, DR) during liver regeneration; Lu+ and Lu- biliary cells show opposite phenotypes in motility and duct formation; overexpression of Lu in Lu- biliary cells confers Lu+ phenotype; Lu-deficient mice show severe defects in DR.\",\n      \"method\": \"Isolation of Lu+ and Lu- biliary cells, in vitro duct formation and motility assays, Lu overexpression in Lu- cells, Lu knockout mouse liver injury model\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function, loss-of-function (KO mouse), and primary cell assays across multiple disease models\",\n      \"pmids\": [\"30059007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BCAM defines a primitive cytotrophoblast progenitor state in early placental development; BCAM enrichment or gene silencing results in enhanced or diminished organoid growth, respectively, establishing BCAM as a functional regulator of trophoblast progenitor maintenance.\",\n      \"method\": \"Single-cell RNA sequencing, lineage trajectory analysis, human trophoblast stem cell organoids, BCAM gain-of-function (enrichment) and loss-of-function (siRNA silencing) with organoid growth readout\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — scRNA-seq trajectory defines state, with functional validation by both gain- and loss-of-function in organoid system\",\n      \"pmids\": [\"35020896\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BCAM expression in limbal epithelial progenitor cells is required for cellular migration and differentiation of corneal epithelium; BCAM is functionally required (knockdown impairs migration and differentiation), and its expression is regulated by the transcription factor p63.\",\n      \"method\": \"FACS isolation of BCAM+ cells, holoclone formation assay, corneal epithelial sheet generation, BCAM knockdown loss-of-function for migration and differentiation, ChIP or reporter assays for p63 regulation\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined phenotypic readouts, upstream regulator identified, functional in primary progenitor system\",\n      \"pmids\": [\"35947947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Histone lysine lactylation (Kla) epigenetically induces BCAM expression in oral squamous cell carcinoma (OSCC), and BCAM promotes tumor invasion, angiogenesis, and cisplatin resistance.\",\n      \"method\": \"TCGA/GEO database analysis, Cox model construction, functional assays for invasion, angiogenesis, and drug resistance in BCAM-manipulated OSCC cells\",\n      \"journal\": \"Oral diseases\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3–4 — bioinformatics-driven with some functional follow-up but limited mechanistic detail in the abstract\",\n      \"pmids\": [\"39503345\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BCAM (Lutheran/basal cell adhesion molecule) is an immunoglobulin superfamily transmembrane glycoprotein that functions as a high-affinity receptor for laminin α5 chain; its adhesive activity is regulated post-translationally by PKA-dependent phosphorylation of its cytoplasmic tail (activated via the β2-adrenergic receptor/cAMP/Epac/Rap1 signaling axis), negatively regulated by interaction of its RK573-574 motif with spectrin and by cis-inhibition from glycophorin-C sialic acids, and it engages in heterotypic interactions including binding to α4β1 integrin on reticulocytes (promoting sickle cell–endothelium adhesion), serving as the cell-surface receptor for E. coli CNF1 toxin (via Ig-like domain 2, KD ~2.8 nM), and forming an oncogenic constitutively active membrane-tethered kinase fusion (BCAM-AKT2) in high-grade serous ovarian carcinoma; it also regulates cytoskeletal remodeling through a laminin 511/521 → Lu/BCAM → αII-spectrin → RhoA → actin stress fiber pathway and plays functional roles in trophoblast progenitor maintenance and corneal epithelial differentiation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"BCAM (Lutheran/basal cell adhesion molecule) is an immunoglobulin superfamily transmembrane glycoprotein that functions as a high-affinity laminin α5-chain receptor and mediates cell–matrix and cell–cell adhesion in erythrocytes, endothelium, epithelia, and trophoblast progenitor cells [PMID:7954395, PMID:12506027, PMID:35020896, PMID:35947947]. Its adhesive activity is positively regulated by β2-adrenergic receptor/cAMP/Epac/Rap1/PKA signaling, which phosphorylates the cytoplasmic tail, and negatively regulated by spectrin binding at the RK573-574 motif and by cis-inhibition from glycophorin-C sialic acids, with spectrin dissociation activating a RhoA–actin stress fiber remodeling pathway [PMID:12506027, PMID:15613546, PMID:20092464, PMID:21434869, PMID:29344581]. BCAM also serves as the high-affinity cell-surface receptor for E. coli CNF1 toxin via its second Ig-like domain (KD ~2.8 nM), engages α4β1 integrin on reticulocytes to promote sickle cell–endothelium adhesion, and forms an oncogenic BCAM–AKT2 fusion kinase in high-grade serous ovarian carcinoma [PMID:24453976, PMID:29267242, PMID:17158232, PMID:25733895]. In tissue homeostasis, BCAM marks and functionally maintains trophoblast and limbal epithelial progenitor populations and regulates biliary ductular reaction during liver regeneration [PMID:35020896, PMID:35947947, PMID:30059007].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Molecular cloning established BCAM as an immunoglobulin superfamily member with a V-V-C2-C2-C2 ectodomain architecture, predicting a role in cell adhesion that became the foundation for all subsequent functional studies.\",\n      \"evidence\": \"cDNA expression cloning, sequence analysis, and FISH mapping to 19q13.2–13.3\",\n      \"pmids\": [\"7954395\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No ligand or binding partner identified at this stage\", \"No functional adhesion assay performed\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstration that epinephrine/cAMP/PKA signaling activates Lu/BCAM-mediated sickle RBC adhesion to laminin established the first signaling pathway controlling BCAM adhesive function and linked the molecule to sickle cell vaso-occlusion.\",\n      \"evidence\": \"Pharmacological stimulation (epinephrine, forskolin), PKA inhibition, and soluble BCAM/Lu blocking in sickle RBC adhesion assays\",\n      \"pmids\": [\"12506027\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific phosphorylation sites on BCAM cytoplasmic tail not mapped\", \"Downstream signaling intermediates between PKA and BCAM activation unresolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identification of Epac/Rap1 as the cAMP-dependent intermediate upstream of BCAM activation resolved the signaling cascade as β2AR → cAMP → Epac → Rap1 → Lu/BCAM, distinct from integrin-dependent pathways.\",\n      \"evidence\": \"Epac-specific cAMP analog stimulation, GTP-Rap1 pulldown, adhesion blockade with soluble BCAM/Lu and anti-BCAM antibody in sickle RBCs\",\n      \"pmids\": [\"15613546\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct physical interaction between Rap1 effectors and BCAM not shown\", \"Whether Rap1 acts on BCAM trafficking or conformation remains unresolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Discovery that endothelial Lu/BCAM serves as a counter-receptor for α4β1 integrin on sickle RBCs under flow revealed a heterotypic adhesion axis contributing to vaso-occlusion beyond the laminin interaction.\",\n      \"evidence\": \"Flow-based adhesion assays with Lu-Fc chimeric protein, integrin activation, and soluble Lu-Fc blockade on primary HUVECs\",\n      \"pmids\": [\"17158232\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding site on Lu/BCAM for α4β1 not mapped\", \"Relative contribution of Lu/BCAM–integrin vs. Lu/BCAM–laminin axes in vivo not quantified\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"JAK2 V617F in polycythemia vera was shown to constitutively phosphorylate and upregulate Lu/BCAM, establishing a disease mechanism for abnormal erythrocyte adhesion in myeloproliferative neoplasms.\",\n      \"evidence\": \"Flow cytometry, adhesion assays, and K562 cells transfected with JAK2 V617F, with anti-Lu/BCAM blocking\",\n      \"pmids\": [\"17412890\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct JAK2-BCAM substrate relationship not demonstrated with purified kinase\", \"Whether JAK2 V617F acts on the same cytoplasmic tail sites as PKA is unclear\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identification of the spectrin-binding RK573-574 motif as a negative regulator of BCAM adhesion explained how cytoskeletal anchorage restrains BCAM activity and why hereditary spherocytosis RBCs show enhanced laminin binding.\",\n      \"evidence\": \"Triton extraction, site-directed mutagenesis (RK573-574AA) in K562 cells, and flow-based adhesion assays\",\n      \"pmids\": [\"20092464\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of spectrin–BCAM interaction not resolved\", \"Whether PKA phosphorylation and spectrin binding are coordinated or independent remains unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Extending the spectrin-BCAM axis to non-erythroid cells, disruption of the RK573-574 motif was shown to enhance BCAM surface half-life and trigger a laminin 511/521 → Lu/BCAM → αII-spectrin → RhoA → actin stress fiber pathway, linking BCAM to cytoskeletal remodeling.\",\n      \"evidence\": \"Co-IP of αII-spectrin with BCAM, RK573-574AA mutagenesis in MDCK cells, RhoA activation assay, phalloidin staining\",\n      \"pmids\": [\"21434869\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intermediary GEF connecting BCAM/spectrin disruption to RhoA activation not identified\", \"Relevance of this pathway in vivo not tested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"BCAM was identified as a transcriptional target repressed by the 14-3-3β–FBI1/Akirin2 oncogenic complex, and BCAM overexpression abolished anchorage-independent growth and tumorigenicity in hepatoma cells, revealing a context-dependent tumor-suppressive role.\",\n      \"evidence\": \"Microarray, ChIP for promoter binding, BCAM overexpression in K2 hepatoma cells with soft agar, migration, invasion, and xenograft assays\",\n      \"pmids\": [\"24223164\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which BCAM suppresses anchorage-independent growth not defined\", \"Whether BCAM tumor-suppressive function depends on laminin binding unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of Lu/BCAM as the essential cell-surface receptor for E. coli CNF1 toxin opened an unexpected role in host–pathogen interaction, with subsequent biophysical mapping placing the binding site on Ig-like domain 2 at 2.8 nM affinity.\",\n      \"evidence\": \"Co-precipitation with tagged toxin, Lu/BCAM-deficient cell assays (2014); SPR and SAXS stoichiometry determination (2017)\",\n      \"pmids\": [\"24453976\", \"29267242\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural model of the BCAM–CNF1 interface at atomic resolution not available\", \"Whether BCAM mediates CNF1 internalization or only surface binding is not fully resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Hydroxycarbamide was shown to reduce sickle cell adhesion by activating PDE4A to lower cAMP and decrease endothelial Lu/BCAM phosphorylation, providing a pharmacological mechanism linking to the PKA/Epac signaling axis.\",\n      \"evidence\": \"Adhesion assays on HC-treated endothelial cells, PDE4A expression, cAMP measurement, Lu/BCAM phosphorylation analysis\",\n      \"pmids\": [\"24616094\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific phosphorylation site(s) reduced by HC not mapped\", \"In vivo relevance of PDE4A-BCAM axis in treated sickle cell patients not confirmed\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Discovery of the recurrent BCAM–AKT2 fusion in ~7% of high-grade serous ovarian carcinomas demonstrated that BCAM's transmembrane domain can tether AKT2 kinase to the membrane, generating a constitutively active oncogenic kinase.\",\n      \"evidence\": \"RNA-seq fusion detection, RT-PCR, Western blot, kinase activity assay, CRISPR/Cas9-generated translocation in OVCAR8/HEK-293T, focus formation assay\",\n      \"pmids\": [\"25733895\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream AKT2 substrates specifically activated by the fusion not characterized\", \"Whether wild-type BCAM contributes to ovarian cancer biology independent of the fusion unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"BCAM–LAMA5 interaction was shown to mediate KRAS-mutant colorectal cancer cell adhesion to endothelium and hepatic metastasis, extending the BCAM–laminin α5 adhesion axis to metastatic colonization.\",\n      \"evidence\": \"Phage display, siRNA knockdown, peptide competition, and in vivo mouse metastasis model\",\n      \"pmids\": [\"27143691\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BCAM on tumor cells or endothelium is the critical partner in metastasis not fully dissected\", \"Selectivity of BCAM-mimic peptides for KRAS-mutant vs. KRAS-wild-type tumors not established\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Glycophorin-C sialic acids were identified as cis-inhibitors of BCAM adhesion, with loss of sialylation (neuraminidase or Gerbich phenotype) releasing BCAM to engage laminin α5; the sialic acid-binding site was mapped to the third Ig-like domain.\",\n      \"evidence\": \"Neuraminidase treatment, Gerbich phenotype donor RBCs, Co-IP of glycophorin-C with Lu/BCAM, and domain mapping\",\n      \"pmids\": [\"29344581\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic-level structure of the sialic acid–Ig3 interaction not solved\", \"Whether glycophorin-C cis-inhibition operates in non-erythroid cells unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Lu/BCAM was shown to distinguish functional biliary cell subsets and to be required for ductular reaction during liver regeneration, extending BCAM biology to tissue repair.\",\n      \"evidence\": \"Isolation of Lu+ and Lu− biliary cells, in vitro duct formation, Lu overexpression rescue, and Lu-knockout mouse liver injury model\",\n      \"pmids\": [\"30059007\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BCAM signals through laminin α5 or an alternative ligand in biliary regeneration not determined\", \"Downstream transcriptional programs driven by BCAM in biliary cells not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"BCAM was established as a functional marker of primitive cytotrophoblast progenitors and limbal epithelial stem cells, with loss-of-function impairing progenitor maintenance, migration, and differentiation in organoid and sheet culture systems.\",\n      \"evidence\": \"scRNA-seq lineage trajectories, gain- and loss-of-function in trophoblast organoids (2022a); FACS, BCAM knockdown, and p63 ChIP in limbal epithelial cells (2022b)\",\n      \"pmids\": [\"35020896\", \"35947947\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling downstream of BCAM in progenitor maintenance not characterized\", \"Whether BCAM ligand engagement (laminin α5) is required for the progenitor phenotype not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of BCAM–laminin α5 and BCAM–spectrin interactions at atomic resolution, the identity of the GEF linking BCAM/spectrin to RhoA, how PKA phosphorylation and spectrin release are coordinated, and whether BCAM's progenitor-maintenance role in trophoblast and limbal cells proceeds through the same downstream signaling as its erythrocyte adhesion function.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution co-crystal structure of BCAM with any partner\", \"Downstream signaling in progenitor/stem cell contexts not defined\", \"In vivo genetic models addressing BCAM in sickle cell vaso-occlusion lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [0, 1, 3, 6, 7, 12]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [9, 13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1, 3, 6, 11, 14, 15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0000000\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 2, 5, 10]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [3, 6, 7, 12]},\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [1, 6, 7, 12, 15]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 11, 19]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"LAMA5\",\n      \"SPTA1\",\n      \"GYPC\",\n      \"ITGA4\",\n      \"RAP1A\",\n      \"AKT2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}